NLS Pharmaceutics Director Resigns, Board Seat Not Replaced
Ticker: NCEL · Form: 6-K · Filed: Apr 8, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, resignation
TL;DR
NLS Pharma director Walsh out as of 4/3, they aren't replacing him.
AI Summary
On April 3, 2024, NLS Pharmaceutics Ltd. announced the resignation of Dr. Anthony S. Walsh from its board of directors. The company does not plan to fill his vacant seat and stated that Dr. Walsh's departure was not due to any disagreements regarding the company's operations or policies. NLS Pharmaceutics expressed gratitude for his contributions.
Why It Matters
The departure of a board member, even without stated disagreement, can signal internal shifts or strategic decisions within a company. The decision not to replace the director may indicate a streamlining of governance or a change in board structure.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a board member's resignation without any indication of financial distress or significant strategic change.
Key Players & Entities
- Anthony S. Walsh, Ph.D. (person) — Resigned board member
- NLS Pharmaceutics Ltd. (company) — Registrant company
- April 3, 2024 (date) — Date of resignation
FAQ
Who resigned from the NLS Pharmaceutics Ltd. board of directors?
Mr. Anthony S. Walsh, Ph.D. resigned from the board of directors.
When did Mr. Walsh's resignation take effect?
Mr. Walsh resigned on April 3, 2024.
Does NLS Pharmaceutics Ltd. plan to appoint a new board member to replace Mr. Walsh?
No, the Registrant does not intend to replace Mr. Walsh with a new member of the Board.
Were there any material disagreements that led to Mr. Walsh's resignation?
No, Mr. Walsh's resignation was not based on any material disagreement with the Registrant on any matter relating to its operations, policies or practice.
What is the company's principal executive office address?
The company's principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
Filing Stats: 278 words · 1 min read · ~1 pages · Grade level 9.2 · Accepted 2024-04-08 16:11:38
Filing Documents
- ea0203502-6k_nlspharma.htm (6-K) — 9KB
- 0001213900-24-031179.txt ( ) — 10KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: April 8, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer